Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]

Journal of Bone and Mineral Research

Volumn 23, Issue 12, 2008, Pages 2033-2039

  Vahle, John L ^a   Zuehlke, Ulrich ^b   Schmidt, Allen ^a   Westmore, Michael ^a   Chen, Peiqi ^a   Sato, Masahiko ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Covance Laboratories ^*  (Germany)

Author keywords

Bone; Monkey; Osteosarcoma; PTH; Teriparatide

Indexed keywords

PARATHYROID HORMONE[1-34];

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CANCER; BONE MASS; BONE RADIOGRAPHY; CANCER CHEMOTHERAPY; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; EXPERIMENTAL ANIMAL; FEMALE; FOLLOW UP; LONG TERM CARE; MONKEY; NONHUMAN; OSTEOSARCOMA; TREATMENT DURATION;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE NEOPLASMS; CELL PROLIFERATION; FEMALE; FEMUR; MACACA FASCICULARIS; TERIPARATIDE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 56749181173     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080807     Document Type: Article

References (23)

1. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
2. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore M, Ma L, Nold JB 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone(1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312-321.
3. Sato M, Vahle J, Schmidt A, Westmore M, Smith S, Rowley E, Ma LY 2002 Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology 143:3230-3242.
4. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M 2004 Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426-438.
5. Jolette J, Wilker CE, Smith SY, Doyle N, Hardisty JF, Metcalfe AJ, Marriott TB, Fox J, Wells DS 2006 Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol 34:929-940.
6. Tashjian AH, Chabner BA 2002 Clinical safety of recombinant human parathyroid hormone (1-34) in the treatment of osteoporosis in postmenopausal women and men. J Bone Miner Res 17:1151-1161.
7. Tashjian AH Jr, Gagel RF 2006 Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 21:354-365.
8. Tashjian AH Jr, Goltzman D 2008 On the interpretation of rat carcinogenicity studies for human parathyroid hormone (1-34) and human parathyroid hormone (1-84). J Bone Miner Res 21:354-365.
9. Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R 2001 Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28:150-159.
10. Sato M, Westmore M, Clendenon J, Smith S, Hannum B, Zeng GQ, Brommage R, Turner CH 2000 Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques. Osteoporos Int 11:871-880.
11. Sato M, Westmore M, Ma YL, Schmidt A, Zeng QQ, Glass EV, Vahle J, Brommage R, Jerome CP, Turner CH 2004 Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res 19:623-629.
12. Turner CH, Burr DB 1993 Basic biomechanical measurements of bone: A tutorial. Bone 14:595-608.
13. Jerome CP, Johnson CS, Vafai HT, Kaplan KC, Bailey J, Capwell B, Fraser F, Hansen L, Ramsay H, Shadoan M, Lees CJ, Thomsen JS, Mosekilde L 1999 Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 25:301-309.
14. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM 2001 Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157-165.
15. Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY 2007 Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J Bone Miner Res 22:260-273.
16. Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH 2004 Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164:2024-2030.
17. Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH 2005 Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507-1513.
18. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ 2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555-565.
19. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129-2134.
20. Ejersted C, Oxlund H, Eriksen EF, Andreassen TT 1998 Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats. Bone 23:43-52.
21. Kaufman JM, Orwoll E, Goemaere S, San MJ, Hossain A, Dalsky GP, Lindsay R, Mitlak BH 2005 Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy. Osteoporos Int 16:510-516.
22. Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP 2004 The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 15:992-997.
23. Adami S, San Martin J, Muñoz-Torres M, Econs MJ, Xie L, Dalsky GP, McClung M, Felsenberg D, Brown JP, Brandi ML, Sipos A 2008 Effect Of Raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 19:87-94.